{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shearer J"],"funding":["Partenariat Canadien Contre Le Cancer","Alberta Health","Alberta Cancer Foundation","Mitacs","European Commission","Funda??o para a Ci?ncia e a Tecnologia","Alberta Health Services","Canadian Institutes of Health Research"],"pagination":["991-1001"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11040554"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(4)"],"pubmed_abstract":["Human gut microbiota are recognized as critical players in both metabolic disease and drug metabolism. However, medication-microbiota interactions in cardiometabolic diseases are not well understood. To gain a comprehensive understanding of how medication intake impacts the gut microbiota, we investigated the association of microbial structure with the use of single or multiple medications in a cohort of 134 middle-aged adults diagnosed with cardiometabolic disease, recruited from Alberta's Tomorrow Project. Predominant cardiometabolic prescription medication classes (12 total) were included in our analysis. Multivariate Association with Linear Model (<i>MaAsLin2</i>) was employed and results were corrected for age, BMI, sex, and diet to evaluate the relationship between microbial features and single- or multimedication use. Highly individualized microbiota profiles were observed across participants, and increasing medication use was negatively correlated with α-diversity. A total of 46 associations were identified between microbial composition and single medications, exemplified by the depletion of <i>Akkermansia muciniphila</i> by β-blockers and statins, and the enrichment of <i>Escherichia</i>/<i>Shigella</i> and depletion of <i>Bacteroides xylanisolvens</i> by metformin. Metagenomics prediction further indicated alterations in microbial functions associated with single medications such as the depletion of enzymes involved in energy metabolism encoded by <i>Eggerthella lenta</i> due to β-blocker use. Specific dual medication combinations also had profound impacts, including the depletion of <i>Romboutsia</i> and <i>Butyriciocccus</i> by statin plus metformin. Together, these results show reductions in bacterial diversity as well as species and microbial functional potential associated with both single- and multimedication use in cardiometabolic disease."],"journal":["ACS pharmacology & translational science"],"pubmed_title":["Microbial Features Linked to Medication Strategies in Cardiometabolic Disease Management."],"pmcid":["PMC11040554"],"funding_grant_id":["2816ERA13E","2816ERA14E","150364"],"pubmed_authors":["Shen-Tu G","Laudes M","Shearer J","Shah S","Schlicht K","Mu C"],"additional_accession":[]},"is_claimable":false,"name":"Microbial Features Linked to Medication Strategies in Cardiometabolic Disease Management.","description":"Human gut microbiota are recognized as critical players in both metabolic disease and drug metabolism. However, medication-microbiota interactions in cardiometabolic diseases are not well understood. To gain a comprehensive understanding of how medication intake impacts the gut microbiota, we investigated the association of microbial structure with the use of single or multiple medications in a cohort of 134 middle-aged adults diagnosed with cardiometabolic disease, recruited from Alberta's Tomorrow Project. Predominant cardiometabolic prescription medication classes (12 total) were included in our analysis. Multivariate Association with Linear Model (<i>MaAsLin2</i>) was employed and results were corrected for age, BMI, sex, and diet to evaluate the relationship between microbial features and single- or multimedication use. Highly individualized microbiota profiles were observed across participants, and increasing medication use was negatively correlated with α-diversity. A total of 46 associations were identified between microbial composition and single medications, exemplified by the depletion of <i>Akkermansia muciniphila</i> by β-blockers and statins, and the enrichment of <i>Escherichia</i>/<i>Shigella</i> and depletion of <i>Bacteroides xylanisolvens</i> by metformin. Metagenomics prediction further indicated alterations in microbial functions associated with single medications such as the depletion of enzymes involved in energy metabolism encoded by <i>Eggerthella lenta</i> due to β-blocker use. Specific dual medication combinations also had profound impacts, including the depletion of <i>Romboutsia</i> and <i>Butyriciocccus</i> by statin plus metformin. Together, these results show reductions in bacterial diversity as well as species and microbial functional potential associated with both single- and multimedication use in cardiometabolic disease.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T22:52:06.769Z","creation":"2025-04-05T11:34:18.317Z"},"accession":"S-EPMC11040554","cross_references":{"pubmed":["38665607"],"doi":["10.1021/acsptsci.3c00261"]}}